News Category
Onco-Innovations has signed a letter of intent to potentially acquire exclusive rights to Ifowonco's oral small-molecule LAG-3 inhibitor, a move that ...
Creative Biolabs has broadened its complement assay service portfolio, offering advanced tools to evaluate complement pathway activity and therapeutic...
Quantum BioPharma's Lucid-MS targets myelin degradation to address progression independent of relapse activity in multiple sclerosis, offering a novel...
Silo Pharma's receipt of a Canadian patent allowance for its lead PTSD asset SPC-15 underscores the company's expanding international intellectual pro...
Quantum BioPharma's Lucid-MS, a novel therapy aiming to protect myelin without immune suppression, has received FDA clearance for phase 2 trials, pote...
Regentis Biomaterials' receipt of a Japanese Notice of Allowance for its GelrinC manufacturing process strengthens its global IP portfolio and support...
VERAXA Biotech's collaboration with AI firm Ardigen aims to enhance its oncology pipeline by using artificial intelligence to identify optimal drug ta...
VERAXA Biotech's collaboration with Ardigen uses AI to optimize its BiTAC platform, potentially improving target validation and reducing development r...
The American Heart Association is accepting applications for its 2026 Health Tech Competition to accelerate market-ready technologies that improve car...
Researchers have identified a protein on glioblastoma cells that could be targeted to make the cancer more vulnerable to existing treatments, potentia...
NanoViricides expects to commence a Phase II clinical trial of its oral antiviral NV-387 for Ebola in the DRC, potentially offering a more accessible ...
Helus Pharma's appointment of Regina Donohue as Chief People Officer and Suresh Durgam to its Scientific Advisory Board underscores its commitment to ...
Cayenne Wellness Center's 20th Annual Sickle Cell Disease Educational Summit, themed '20/20 Vision: Our Legacy Continues,' underscores two decades of ...
Helix BioPharma's appointment of Dr. Markus Loeffler as CMO signals a strategic push to advance its lead candidate L-DOS47 and prepare LEUMUNA for cli...
Quantum BioPharma's significant expense reductions and FDA approval for its Lucid-MS Phase 2 trial mark a critical step toward a potential treatment f...
Regentis Biomaterials is advancing its cartilage repair product GelrinC through pivotal US trials while simultaneously commercializing in Europe, aimi...
Alpha Cognition's second-quarter results show strong demand for ZUNVEYL, with revenue up 71% sequentially, positioning the company for growth despite ...
The Lung Cancer Foundation of America and the International Association for the Study of Lung Cancer have awarded $200,000 each to two early-career sc...
PX1 Research's domestic cGMP manufacturing and seven-stage testing protocol ensure 99%+ purity for research peptides, addressing supply chain quality ...
A comprehensive review in the World Journal of Pediatric Surgery emphasizes individualized, bowel-preserving surgical approaches and emerging adjuncts...
Onco-Innovations is advancing its precision oncology candidate ONC010 through key manufacturing and metabolic studies, positioning it for first-in-hum...
Regentis Biomaterials' GelrinC, a cell-free hydrogel implant, gains European approval for a scalable manufacturing process and progresses U.S. trials,...
A new study reveals that a small group of immune cells is crucial for mobilizing the immune system against cancer, which could inform future therapies...
Quantum BioPharma reports a significant reduction in operating expenses and FDA clearance for its Phase 2 trial of Lucid-MS, a potential treatment for...
Regentis Biomaterials is simultaneously advancing its cartilage repair product GelrinC through U.S. clinical trials and European commercialization, wi...
Lantern Pharma reported Q2 2026 results, highlighting progress in its AI-driven oncology pipeline and the establishment of Open Medicine AI as a separ...
Helus Pharma completes enrollment in its pivotal Phase 3 APPROACH trial for HLP003 in major depressive disorder, with topline data expected in Q4 2026...
DM Clinical Research marks two decades of growth, having enrolled over 35,000 patients and expanding to 35+ sites, highlighting its impact on accelera...
NeOnc Technologies' NEO100 met its primary endpoint in a Phase 2a study for recurrent brain cancer, showing significant survival benefits and position...
PX1 Research's new batches of Retatrutide and Tirzepatide peptides, manufactured under cGMP standards and verified by HPLC, offer researchers high-pur...
Quantum BioPharma's Lucid-MS focuses on inhibiting myelin degradation to address progression independent of relapse activity, a key driver of long-ter...
GeoVax highlights its MVA-based hemorrhagic fever vaccine candidates and expertise as the Democratic Republic of Congo faces the fastest-growing Ebola...
Amid looming tariffs on drug imports, global pharmaceutical companies are investing approximately $500 billion in U.S. facilities, which could reshape...
Nutriband's CEO will showcase its AVERSA abuse-deterrent transdermal technology at the 2026 Georgia Life Sciences Summit, underscoring the company's r...
Quantum BioPharma's FDA clearance to advance Lucid-MS into Phase 2 trials marks a significant step toward a potential neuroprotective treatment for mu...
PX1 Research introduces a new line of US-manufactured sublingual peptide strips, including retatrutide, tirzepatide, and BPC-157, offering a needle-fr...
PX1 Research's new seven-stage HPLC purity verification and cGMP-aligned domestic production ensure batch-specific documentation, addressing transpare...
NanoViricides has received approval to begin a Phase II trial of its oral antiviral NV-387 for Ebola in the DRC, potentially offering a more practical...
New research from the University of Virginia suggests focused ultrasound could make cancer drugs more effective against gliomas, potentially leading t...
Telomir Pharmaceuticals' peer-reviewed preclinical data demonstrates Telomir-Zn's potential to suppress tumor growth and metastasis in TNBC models, su...
Quantum BioPharma's FDA clearance to initiate Phase 2 trials for Lucid-MS, a novel neuroprotective candidate for multiple sclerosis, marks a pivotal s...
Tonix Pharmaceuticals' Q2 2026 revenue surged to $13.5 million driven by TONMYA sales, marking a significant milestone in the fibromyalgia treatment m...
Tonix Pharmaceuticals' second-quarter revenue jumped to $13.5 million, driven by TONMYA's strong market uptake for fibromyalgia, signaling a significa...
Tonix Pharmaceuticals' Q2 2026 revenue jumped to $13.5 million, driven by TONMYA sales, signaling successful market adoption and financial stability f...
A new narrative review provides a comprehensive framework for risk-adapted diagnosis and treatment of neuroblastoma, emphasizing molecular and clinica...
Regentis Biomaterials is progressing its GelrinC cartilage regeneration technology through clinical trials, FDA submission preparation, European comme...
Quantum BioPharma's two-pronged approach to neurological health, including its investigational MS therapy Lucid-MS and the supplement unbuzzd, could r...
Quantum BioPharma advances its two-pronged approach to neurological health with Lucid-MS for multiple sclerosis and unbuzzd for alcohol misuse, highli...
